+ All Categories
Home > Documents > Lactobacillus plantarum LP

Lactobacillus plantarum LP

Date post: 31-Oct-2021
Category:
Upload: others
View: 23 times
Download: 0 times
Share this document with a friend
2
About Lactobacillus plantarum LP LDL ® Technical information LP LDL ® is a naturally-occurring strain of the bacterial species Lactobacillus plantarum. Lactobacilli are common components of the human intestinal microbiome and have traditionally been used as probiotics 1 . LP LDL ® was selected using OptiBiotix’s OptiScreen® proprietary technology platform from a collection of over 4,000 microbial candidates for its outstanding capacity to hydrolyse bile salts. This activity is crucial for bacterial survival in the harsh conditions of the intestine and mediates LP LDL ®’s mechanism of action. An independent, double blind, randomised, placebo-controlled human study with LP LDL ® was performed by the University of Reading (United Kingdom) with 50 hypercholesterolemic subjects, which were administered with a daily dose of 4x10 9 cfu of LP LDL ® or placebo 2 . In the active group, LP LDL ® showed to be completely safe and well tolerated and provide the following results: Fully-sequenced genome Safety profile tested in silico (genomic assessment of antibiotic sensitivity, absence of virulence and pathogenicity factors), in vitro (phenotypic antibiotic sensitivity according to EFSA’s guidelines 3 , biogenic amines and D-lactate production) and in vivo (human study 2 ) Outstanding survival and metabolic activity in high concentrations of bile salts and conditions in the intestine Excellent survival to freeze-drying and stability at 25ºC and 5ºC over 24 months* Manufactured under pharmaceutical-grade GMP conditions Registered at the European Culture General Collection with accession number ECGC 13110402. Protected worldwide by OptiBiotix patents and trademarks Self-determined GRAS Lactobacillus plantarum The liver and the microorganisms of the gut microbiome have an intense functional and bidirectional communication known as the Gut-Liver Axis. In this metabolic cooperation, the liver produces and releases bile salts influencing cholesterol metabolism. It is now known that certain microbes, such as LP LDL ®, are able to metabolise bile salts, releasing metabolites that interact with the human body. This activity can help regulate high cholesterol and blood pressure and is involved in the regulation of physiological processes such as glucose regulation, vitamin metabolism and liver function About the Gut-Liver Axis Blood Pressure -5.1% HDL +4.5% -13.9% LDL -36.7% Total Cholesterol -40 -35 -30 -25 -20 -15 -10 -5 0 5 10 % change LP LDL ® Lactobacillus plantarum LP LDL ® mechanism of action: Bile Salt Hydrolysis without LP LDL ® W i t h o u t Bile Salt Hydrolysis enhanced by LP LDL ® W i t h © 2020 ProBiotix Health Limited. All rights reserved. optibiotix.com
Transcript
Page 1: Lactobacillus plantarum LP

About Lactobacillus plantarum LPLDL® Technical information

LPLDL® is a naturally-occurring strain of the bacterial species Lactobacillus plantarum. Lactobacilli are common components of the human intestinal microbiome and have traditionally been used as probiotics1.

LPLDL® was selected using OptiBiotix’s OptiScreen® proprietary technology platform from a collection of over 4,000 microbial candidates for its outstanding capacity to hydrolyse bile salts. This activity is crucial for bacterial survival in the harsh conditions of the intestine and mediates LPLDL®’s mechanism of action.

An independent, double blind, randomised, placebo-controlled human study with LPLDL® was performed by the University of Reading (United Kingdom) with 50 hypercholesterolemic subjects, which were administered with a daily dose of 4x109 cfu of LPLDL® or placebo2. In the active group, LPLDL® showed to be completely safe and well tolerated and provide the following results:

Fully-sequenced genome Safety profile tested in silico (genomic assessment of antibiotic sensitivity, absence of virulence and pathogenicity factors), in vitro (phenotypic antibiotic sensitivity according to EFSA’s guidelines3, biogenic amines and D-lactate production) and in vivo (human study2) Outstanding survival and metabolic activity in high concentrations of bile salts and conditions in the intestine Excellent survival to freeze-drying and stability at 25ºC and 5ºC over 24 months* Manufactured under pharmaceutical-grade GMP conditions Registered at the European Culture General Collection with accession number ECGC 13110402. Protected worldwide by OptiBiotix patents and trademarks Self-determined GRAS

Lactobacillus plantarum

The liver and the microorganisms of the gut microbiome have an intense functional and bidirectional communication known as the Gut-Liver Axis. In this metabolic cooperation, the liver produces and releases bile salts influencing cholesterol metabolism.

It is now known that certain microbes, such as LPLDL®, are able to metabolise bile salts, releasing metabolites that interact with the human body. This activity can help regulate high cholesterol and blood pressure and is involved in the regulation of physiological processes such as glucose regulation, vitamin metabolism and liver function

About the Gut-Liver Axis

Blood Pressure -5.1%

HDL +4.5%

-13.9% LDL-36.7% TotalCholesterol

-40 -35 -30 -25 -20 -15 -10 -5 0 5 10% change

LPLDL®

Lactobacillusplantarum LP

LDL®

mechanism of action:

Bile SaltHydrolysis

withoutLPLDL

®

Without

Bile SaltHydrolysis

enhanced byLPLDL

®

W

ith

© 2020 ProBiotix Health Limited. All rights reserved.

optibiotix.com

Page 2: Lactobacillus plantarum LP

Capsules Tablets Multilayer Tablets

Sachets Sticks Orodispersible Powders

Bottles Blisters

L. ferm

entum 30226

L. ferm

entum 11976

L. casei 30185

L. plantarum 30187

L. rhamnosu

s 30188

L. saliv

arius 1

1741

L. helvetic

us 30224

L. delbrueckii 3

0186

L. saliv

arius 3

0225

% C

hole

ster

ol re

mov

al

0h 4h 12h 24h

40

35

30

25

20

15

10

5

0

LPLDL®Control Control LPLDL®Control

% C

hole

ster

ol re

mov

al

24h8h0h

0

5

10

15

20

25

30

35

3.9375

23.49426.906

4.725

© 2020 ProBiotix Health Limited. All rights reserved.

Supporting literature(1) Salminen et al., 1998; (2) Costabile et al., 2017; (3) EFSA Journal, 2012* Studies ongoing

To find out more please contact OptiBiotix on:

[email protected]

optibiotix.comFor media enquiries please contact:PHD Marketing & Strategy | Tel: +44 1977 708643Email: [email protected] | phdmarketing.co.uk

Cholesterol removal in vitro

Presentation formats available

Probiotic Product of the Year

Best Functional Ingredient Finalist2018

Cholesterol removal in pure culture Cholesterol removal in gut models

OptiBiotix Health PlcOptiBiotix Health Plc | Innovation Centre, Innovation Way, Heslington, York, YO10 5DG, UK.


Recommended